Zydus receives USFDA final approval for Perphenazine Tablets
Zydus Cadila has received final approval from the USFDA to market Perphenazine Tablets USP, 2 mg,
4 mg, 8 mg and 16 mg. (US RLD: Trilafon Tablets)
This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group's formulation manufacturing facility at Baddi.
The group now has 284 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Apr 07 2020 | 1:08 PM IST